Back

Sirolimus vs paclitaxel for femoropopliteal peripheral artery disease - The limus flow randomized trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Peripheral angioplasty and complications Intervention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Christos Rammos

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

4 More presentations in this session

Presentation thumbnail
Pathology of balloon angioplasty for below the knee arteries in patients with chronic limb threatening ischemia
Doctor M. Shiozaki (Kanagawa, JP)
Abstract Slides Video
Presentation thumbnail
The predictors of clinical outcome in the patients undergoing endovascular intervention for lower extremity peripheral arterial disease
Professor B. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Clinical impact of endovascular therapy with paclitaxel-based strategy for femoropopliteal lesions in chronic limb-threatening ischaemia
Mr H. Nohara (Sakai, JP)
Abstract Slides Video
Presentation thumbnail
Long-term prognosis after bypass surgery versus endovascular therapy in chronic hemodialysis patients with peripheral artery disease -10-year follow-up study
Doctor Y. Kumada (Kasamatsu, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Peripheral angioplasty and complications

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Biolimus-coated balloon or sirolimus-coated balloon vs paclitaxel-coated balloon for in-stent restenosis: a systematic review and meta-analysis
thumbnail
Congress Presentation
Changes of angiography-derived coronary microcirculatory resistance before and after drug-coated balloon treatment
thumbnail
Congress Presentation
Safety and efficacy of low-dose versus high-dose paclitaxel-coated balloons in patients with femoropopliteal lesions: an updated and meta-analysis.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources